key: cord-0896795-usxpmea7
authors: Yakovlev, Alexander S.; Belyaletdinova, Ilmira K.; Mazankova, Lyudmila N.; Samitova, Elmira R.; Osmanov, Ismail M.; Gavelya, Nataly V.; Volok, Viktor P.; Kolpakova, Ekaterina S.; Shishova, Anna A.; Dracheva, Natalia A.; Kozlovskaya, Liubov I.; Karganova, Galina G.; Ishmukhametov, Aydar A.
title: SARS-CoV-2 infection in children in Moscow in 2020: clinical features and impact on circulation of other respiratory viruses
date: 2022-01-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.358
sha: 97231b11bbfd3804c5618a7c7a0062282b0c8746
doc_id: 896795
cord_uid: usxpmea7

Objectives The aim of this study was to estimate the impact of the COVID-19 pandemic on the circulation of non-SARS-CoV-2 respiratory viruses and clinical characteristics of COVID-19 in hospitalized children. Methods 226 and 864 children admitted to Children's City Clinical Hospital with acute respiratory infection in September-November of 2018 and 2020 in Moscow were tested for respiratory viruses using multiplex PCR and Mycoplasma pneumoniae/Chlamydia pneumoniae using ELISA. Results The detection rate of non-SARS-CoV-2 viruses in 2020 was lower than in 2018, 16.9% vs 37.6%. An increase in the median age of children with the respiratory viruses was observed during the pandemic (3 years vs 1 year). There was no significant difference in the frequency of ICU admission among children with SARS-CoV-2 and other respiratory virus infections (2.7% vs 2.9%). SARS-CoV-2 and hRV, hMPV, hAdV showed significantly lower than expected co-detection rates during co-circulation. An increase in BMI or bacterial coinfections lead to an increased risk of ICU admission and a longer duration of COVID-19 in children. Conclusions The COVID-19 pandemic led to significant changes in the epidemiological characteristics of non-SARS-CoV-2 respiratory viruses during the autumn peak of the 2020 pandemic, compared to the same period in 2018.

Acute respiratory infections (ARIs) are a serious public health problem and a leading cause of morbidity and mortality in children worldwide (Williams et al., 2002) . ARIs are associated with a wide range of respiratory viruses such as respiratory syncytial virus (RSV), human metapneumoviruses (hMPV), human adenoviruses (hAdV), human bocaviruses (hBoV), human rhinoviruses (hRV), parainfluenza viruses (PIV), human coronaviruses (hCoV), and others.

On March 11, 2020, the WHO announced the start of the COVID-19 pandemic (World Health Organization, 2020) . Several studies have shown that an influenza pandemic could affect the epidemiology of other respiratory viral infections (RVI). As a result, the prevalence, age distribution, and other epidemiological characteristics of the virus circulation can change (Meningher et al., 2014; Pascalis et al., 2012; Thiberville et al., 2012) .

Another important issue is the impact of coinfections with a pandemic virus on the severity of other RVI. The issue has not yet been sufficiently studied (Lai et al., 2020; Sarkar et al., 2021) . Moreover, there is a limited amount of data on the effect of bacterial infections on the clinical course of COVID-19 (Oliva et al., 2020; Rawson et al., 2020) . This is important for prediction of the disease progression, prognosis, and treatment strategy, especially among high-risk group such as young children.

In the present study we analyzed data and specimens from children hospitalized with ARIs during the COVID-19 pandemic in Moscow, Russia (September -November 2020) and compared them with those obtained for the same period of 2018 to assess the impact of the COVID-19 pandemic on the distribution and clinical characteristics of non-influenza RVI, as well as to assess the epidemiological and clinical features of SARS-CoV-2 infection in Russia.

The study was carried out at the Children's City Clinical Hospital named after Z.A.

Bashlyaeva, Moscow, Russia which is the largest hub of infectious diseases in the city.

Study included participants between 1 month and 18 years old, hospitalized with acute respiratory symptoms from September 27 to November 30 (226 patients in 2018, and 864 in 2020).

Nasopharyngeal swabs were taken from all patients within 24 hours of admission and tested using RT-PCR (AmpliSens ARVI-screen-Fl kit (Interlabservice, Russia) for common respiratory viruses, including RSV, hMPV, hAdV, hBoV, hRV, PIV 1-4, alpha and beta-hCoV. Patients admitted in 2020 were also tested for SARS-CoV-2 (POLYVIR SARS-CoV-2 (Lytech, Russia)). ELISA was used to detect IgM/IgA antibodies to Mycoplasma pneumoniae and Chlamydia pneumoniae in the serum samples.

This study was approved by the Ethics Committee of the Children's City Clinical Hospital named after Z.A. Bashlyaeva (#14 from 13 August 2020). All study participants or their representatives had provided written informed consent.

Data analysis was performed using GraphPad Prism 9.0.0 (GraphPad Software, LLC).

Baseline characteristics of all positive viral detections were analysed using appropriate descriptive statistics. Continuous data are presented as medians and interquartile ranges, and categorical data as numbers and percentages. Chi-square test or Mann-Whitney test were used for comparisons (significance threshold, P < 0.05).

First, we compared the incidence of infections caused by respiratory viruses, including RSV, hMPV, hAdV, hRV, hBoV, PIV 1-4, alpha and beta-hCoV and SARS-CoV-2 in September-November of 2018 and 2020. The detection rate of RVI in 2018 was lower than in 2020, 37.6% vs 49.3% (Сhi-square test, P < 0.05). However, when we excluded patients with SARS-CoV-2, the detection rate of RVI in 2018 became higher: 37.6% vs 16.9% in 2020 (Сhi-square test, P < 0.05). Then we compared the detection rates of individual non-SARS-CoV-2 RVI in the same periods in 2018 and 2020 (Table 1) .

Detection rates of hRV, hAdV, PIV 3 and hBoV were significantly higher in 2018 compared to 2020. However, the detection rate of hMPV was greater in 2020 (Сhisquare test, all P < 0.05). The incidence of bacterial-viral coinfections did not differ significantly between 2018 and 2020.

We assessed age distribution of patients hospitalized with ARI in 2018 and 2020. A significant increase in the age of children suffering from RVI was observed during the SARS-CoV-2 pandemic (the median age was 1 year [IQR 0.75-2] in 2018 vs 3 years [IQR 1-5] in 2020) (Mann-Whitney test, P <0.001).

We compared the prevalence of respiratory viruses in different age groups before and during the pandemic. Higher rates were observed in 2018 compared to 2020 in patients up to three years of age, but in patients older than three years the rates were lower (Chisquare test, P < 0.0001) (Table S1 ).

There was a significant increase in the proportion of children over three years of age with hRV infection in 2020 compared to 2018 (46.4% vs 12.9%) (Chi-square test, Mycoplasma pneumoniae, were detected in 7.7% cases of COVID-19. SARS-CoV-2 was co-detected with another respiratory virus in 3.1% of cases, whereas non-SARS-CoV-2 respiratory virus coinfections were detected in 6.5% (Сhi-square test, P = 0.1082). There was both viral and bacterial coinfection in one case of COVID-19.

The age distribution of patients with SARS-CoV-2 infection was significantly different from other RVI registered in 2020. The median age of patients with non-SARS-CoV-2 RVI was 3 years [IQR 1-5] vs 10 years in patients with SARS-CoV-2 (Mann-Whitney test, P < 0.001). About 85% of patients infected with respiratory viruses were infants and children under 7 years of age (Table 2) , while more than 66% of cases of SARS-CoV-2 infection occurred in children over 7 years of age. Moreover, the number of detected infections increased with age (Fig. 2) . It is worth noticing that SARS-CoV-2 accounted for 88.9% of the total number of viruses identified in children over 7 years old vs 43.3% in children under 7 years old (Chi-square test, P < 0.05). More than 93% of cases of RVI were detected in children under 7 years of age in 2018.

The most common symptoms of COVID-19 in children were fever, cough, runny nose and fatigue (Fig. 3) . Fever duration of 7 days or more was observed in 25.9% of cases.

Anosmia was noted in 10.2% of cases, however, it is difficult for young children to present such complaints. Gastrointestinal manifestations were a common symptom of COVID-19 (overall 20.9%): vomiting was noted in 6.7%, diarrhea and abdominal pain in 7.1%. Upper respiratory tract symptoms were detected more often than lower respiratory tract symptoms (60.8% vs 31%) (Сhi-square test, P < 0.0001). The median duration of illness with SARS-CoV-2 was 14 days [IQR 10-18] vs 11 days [IQR 8-15] for non-SARS-CoV-2 RVI (Mann-Whitney test, P < 0.001).

There was no significant difference in the frequency of ICU admission among children with SARS-CoV-2 and other RVI (2.7% vs 2.9%). The median age among COVID-19 patients required ICU admission was significantly higher than among patients with non-SARS-CoV-2 RVI (13 years [IQR 12; 16] vs 9 month [2;11] (Mann-Whitney test, P < 0.05). It is important that there was not a single case of severe SARS-CoV-2 infection among children under 8 years of age. All patients under 8 years old who required ICU admission were tested positive for other RVI (hRV 75% and PIV 4 25%).

In this study, no significant differences were found when comparing complete blood count (CBC) data from patients infected with SARS-CoV-2 and other respiratory viruses (Table S3) . Lymphocytosis in 38.0% and neutropenia in 21.6% were most often observed in patients with COVID-19, which is typical for the clinical course of viral infections. Leukocytosis was observed in 12.5%, neutrophilia in 10.6%, and an increased CRP levels were noted in 12.9% patients with SARS-CoV-2 infection. We noted a low incidence of leukopenia 4.3% and lymphopenia 2.4%, which was significantly less than previously described (Ma et al., 2021) .

Bacterial or viral coinfections in patients with COVID-19 were detected in 32 cases (11.1%): 22 cases were represented by bacterial pathogens (7.7%), 9 cases were associated with one of the respiratory viruses (3.1%), and there was also one case of simultaneous bacterial and viral coinfection (0.3%). Respiratory virus coinfections comprised 6.5% of all non-SARS-CoV-2 RVI. Viral coinfections with SARS-CoV-2 were represented by hRV (33.3%), hCoV (HKU-1/OC 43) (33.3%), hMPV, PIV 3 and PIV 4 (11.1% each). The median age of patients with viral coinfections was 1 year [IQR 0.7-2.5], while in patients with only SARS-CoV-2 it was 11 years [IQR 3-15] (Mann-Whitney test, P < 0.01). Viral coinfections were not characterized by a more severe course of the COVID-19. There were no cases of ICU admission and, moreover, the duration of the illness, except for the case of coinfection with hRV, was lower than in patients with only SARS-CoV-2: 10 [IQR 5.5-12.5] vs 14 [IQR 10-18] (Mann-Whitney test, P < 0.05) (Fig. 4) . There was a tendency for a longer duration of the illness in coinfection with hRV compared with other viral coinfections.

The median duration of illness in patients with SARS-CoV-2 and hRV coinfections was 18 days , while in patients with other viral coinfections the median was 10 days , respectively. However, this difference was not significant (Mann-Whitney test, P =0.1786), probably due to the small number of cases.

SARS-CoV-2 and hRV showed significantly lower than expected codetection rates during cocirculation. In addition, a significant negative association was found between SARS-CoV-2 and hAdV, SARS-CoV-2 and hMPV (table 3) 

An association between the COVID-19 severity and the presence of bronchial asthma remains unknown. In our study, 8 patients infected with SARS-CoV-2 were diagnosed with bronchial asthma. The median duration of illness in patients with asthma was 14 days ], the same as in patients with COVID-19 without asthma. The incidence of pneumonia also did not differ significantly from the group of patients without bronchial asthma. In addition, there were no cases requiring ICU admission in children with bronchial asthma. There were no cases of bronchial asthma among children with other respiratory viruses.

BMI was classified according to the WHO centile tables into the following categories: underweight (from -1 SD to -3 SD), healthy weight (Normal) and overweight (from +1 SD to +3 SD) (World Health Organization (WHO), n.d.).

There was a tendency for increase in the median duration of illness depending on the BMI; with a normal BMI, the median duration of disease in COVID-19 patients was 14 days, while in patients with increased BMI from +1 SD to +3 SD, it became 15, 16 and 20 days, respectively. Percentage of ICU admissions also increased from 1.5% at normal BMI to 5.4% at +1 SD and to 25% at +3 SD. Lower respiratory tract diseases (LRTD)

were also more common in overweight children 35-37.8% vs 26.3% than in children with normal body weight (Table 4 ).

The group of underweight children should be considered separately. The duration of the illness in all underweight groups was lower than in normal weight group (11.5-13 days vs 14 days). Among all cases of COVID-19 in underweight children, there were no cases requiring ICU admission. However, the groups -2 SD and -3 SD BMI had the highest percentage of LRTD 40-41.6% vs 26.3% in the group of children with normal body weight.

According to the healthcare authorities, the incidence of ARI among the population ranged from 19,505 to 21,664 per 100,000 people in Russia during the last 10 years (Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 2021). The ARI incidence in children was on average 2.8 times higher than the incidence in the total population. In 2020, due to the COVID-19 pandemic, there was a significant increase in the incidence of ARI compared to the previous year (by 11.5%) and to the long-term average incidence -by 8.8%. Our study, which was carried out at the Children's City Clinical Hospital in Moscow, where the overwhelming majority of children with ARI symptoms in the city were hospitalized, shows a similar increase in the ARI incidence among children.

Previous studies have shown that a respiratory virus pandemic can affect circulation, age distribution, and other properties of seasonal RVI (Meningher et al., 2014; Navarro-Marí et al., 2012) , and several studies have provided evidence of respiratory virus interactions during circulation (Ånestad, 1987; Arden et al., 2020; Casalegno et al., 2010; Nickbakhsh et al., 2019; Wu et al., 2020) . Our study demonstrates the impact of the SARS-CoV-2 infection pandemic on the prevalence of other RVI and age distribution of children hospitalized with ARIs, as well as presents clinical features of COVID-19 in children in Moscow, Russia during the autumn wave of the COVID-19 pandemic in 2020 (Fig. S1 ).

We noted a significant decrease in the frequency of detection of non-SARS-CoV-2 RVI among hospitalized children with symptoms of ARIs in the period from September 2020 to November 2020 compared to the same period of 2018 in Russia. This is consistent with the data presented in UK (Poole et al., 2020) . The main reason for the decrease of the detection rate of seasonal RVI was likely connected to the restrictive measures that were taken during the COVID-19 pandemic.

Another possible reason for the decreased detection of non-SARS-CoV-2 RVI could be the interactions between the respiratory viruses themselves. Previously, in some studies it was shown that respiratory viruses could impact the spread of other viruses. For example, it was shown that rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France (Casalegno et al., 2010) . Our research demonstrates that an interference is possible between SARS-CoV-2 and hRV, hAdV and hMPV. This conclusion is based on a comparison of actual and expected rates of codetection of SARS-CoV-2 and other respiratory viruses. The exact mechanism of viral interference is not fully understood but there are several proposed explanations for this phenomenon, including competition of viruses for the host cell entry receptors and resources, and the induction of innate immune response by another virus (Agrawal, 2019; Pinky and Dobrovolny, 2016; Schultz-Cherry, 2015; Wu et al., 2020) .

During the COVID-19 pandemic, we noted a change in the spectrum of seasonal RVI.

There was a higher prevalence of hMPV in 2020, while hRV, PIV 3, hAdV and hBoV prevailed in 2018. Interestingly, during the 2009 influenza A (H1N1) pandemic, there was also an increase in the prevalence of hMPV in young children (Meningher et al., 2014) .

We have shown an increase in the age of children with RVI during the pandemic. If in 2018 the median age of patients was 1 year, in 2020 it was 3 years. The changes were seen also in the distribution of seasonal RVI by age. There was a trend towards an increase in the age of children who had RVI during the COVID-19 pandemic compared with the previous period. There was a significant increase in the proportion of older children infected with hRV, hAdV, PIV 4 and hBoV.

SARS-CoV-2 prevailed among all RVI detected in 2020. The median age of patients with COVID-19 was significantly higher than that of patients with seasonal RVI. It was noted that most of the COVID-19 cases occurred in children over 7 years old, and at the same time, detection rate increased with age. Interestingly, SARS-CoV-2 made up 88.9% of the total number of viruses identified in children over 7 years old.

We observed a milder course of COVID-19 in children, compared with the disease severity seen in adult patients (Docherty et al., 2020; Poole et al., 2020; Richardson et al., 2020) . Among all patients with COVID-19, only 4.5% required ICU admission, and there were no lethal outcomes recorded. At the same time, it was noted that the severe clinical course of COVID-19 mainly occurred in children over 11 years of age, and there was not a single case of requiring ICU admission among infants, which contradicted the previous review reporting more severe clinical courses in infants than in older children (Yasuhara et al., 2020) . In the present study, a severe clinical course of ARI in infants has been associated with hRV and PIV 4. Diseases of the upper respiratory tract were detected more often than the diseases of the lower respiratory tract in children with SARS-CoV-2 infection. The main clinical manifestations were fever, cough, fatigue, and runny nose, which was consistent with other studies (Castagnoli et al., 2020; Mehta et al., 2020) .

Bacterial and viral coinfections can have a serious impact on the severity of the disease.

During the 2009 influenza A pandemic, there was a high percentage of bacterial coinfections in patients who had severe illness and died (Joseph et al., 2013) . Also, previous studies have shown that coinfection of SARS-CoV-2 with influenza virus can lead to a significant increase in the severity of the disease and mortality (Lai et al., 2020; Sarkar et al., 2021) . At the moment, there is no reliable data on the increase of severity of the disease when SARS-CoV-2 is co-detected with non-influenza respiratory viruses.

In our study, the frequency of detection of bacterial and viral coinfections among patients infected with SARS-CoV-2 was consistent with the data of the previous review (Lansbury et al., 2020) . Viral coinfections occurred mainly in young children and the disease was mild. Moreover, we found that the duration of illness, except for the case of coinfection with hRV, was lower than in patients with only SARS-CoV-2. Bacterial coinfections with SARS-CoV-2 were more common in older children and were seen in 26% of cases with a severe clinical course requiring ICU admission.

Recent studies in adults have shown that the severity of disease increases with increasing BMI in COVID-19 patients (Kompaniyets et al., 2021; Simonnet et al., 2020) .

In our study, an association between increased BMI and ICU admission rate was observed in children with COVID-19, which was exemplified by the fact that 25% of +3SD BMI patients required ICU. In addition, obese children had a longer duration of the illness and more often had LRTD. The duration of illness in children with a BMI below normal was shorter than in children with a normal BMI, and there were no cases of severe COVID-19 requiring ICU admission. However, this group was characterized by the highest incidence of LRTD. However, a small number of patients did not allow this to be statistically confirmed.

According to some reports, asthma may increase the risk of a more severe clinical course of COVID-19 (asthma.org.uk, 2021; CDC, 2020; Hartmann-Boyce et al., 2021; Skevaki et al., 2020; Williamson et al., 2020) . In our study, there was no difference in the severity of disease between patients with and without bronchial asthma. Duration of illness, frequency of ICU admission, and the incidence of pneumonia did not differ significantly between the groups. This may be due to the constant use of inhaled glucocorticosteroids, which is associated with a lower risk of severe COVID-19 in people with bronchial asthma (Bloom et al., 2021; Finney et al., 2021) .

The COVID-19 pandemic led to a significant decrease in the detection rate of non-SARS-CoV-2 RVI and changed the age distribution of hospitalized children with ARIs during the autumn peak of pandemic, compared to the same period of 2018. There was no significant difference in the frequency of ICU admission among children with SARS-CoV-2 and other RVI (2.7% vs 2.9%). There were no cases of severe clinical course of COVID-19 among infants. The severe clinical course of ARI in infants has been associated only with hRV and PIV 4, thereby, physicians should be vigilant when these viruses are detected in samples from young children. The possibility of interference between SARS-CoV-2 and hRV, hAdV, hMPV has been shown. An increase in BMI as well as bacterial coinfections lead to an increased risk of ICU admission and a longer duration of COVID-19 in children.

Federation [АААА-А20-120081790043-5]. The expected number of coinfections was defined as the product of the prevalence of virus 1 and the prevalence of virus 2, multiplied by the total sample size. We then used the chi-square test (significance threshold, P < 0.05) to assess whether there was a significant difference between the actual and expected number of coinfections.

* Differences are statistically significant (Chi-square test, P < 0.05). 

Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections

Surveillance of respiratory viral infections by rapid immunofluorescence diagnosis, with emphasis on virus interference

Genotypic diversity, circulation patterns and co-detections among rhinoviruses in Queensland

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

People with Moderate to Severe Asthma

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study

Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Asthma and COVID-19: Review of evidence on risks and management considerations

Bacterial and viral infections associated with influenza

Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death -United States

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

Co-infections in people with COVID-19: a systematic review and meta-analysis

The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review

SARS-CoV-2 (COVID-19): What Do We Know about Children? A Systematic Review

Relationships between A(H1N1)pdm09 influenza infection and infections with other respiratory viruses

Circulation of other respiratory viruses and viral co-infection during the 2009 pandemic influenza

Virusvirus interactions impact the population dynamics of influenza and the common cold

Coinfection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

Intense Co-Circulation of Non-Influenza Respiratory Viruses during the First Wave of Pandemic Influenza pH1N1/2009: A Cohort Study in Reunion Island

Coinfections of the respiratory tract: Viral competition for resources

SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study

Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Impact of COVID-19 in patients with concurrent coinfections: A systematic review and meta-analyses

Viral Interference: The Case of Influenza Viruses

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Asthma-associated risk for COVID-19 development

The viral etiology of an influenza-like illness during the 2009 pandemic

Estimates of world-wide distribution of child deaths from acute respiratory infections

Factors associated with COVID-19-related death using OpenSAFELY

Situation Report -51

WHO body mass index for age bmi for age

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: